A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. David Kindness is a Certified Public ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Investopedia / Jake Shi A restatement ...

Excellergy, a biotech developing a new class of allergy therapeutics, has announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class effector cell response ...

The "Biotechnology Market - Therapeutic Innovations & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.